Ann: Appendix 4C and Quarterly Update, page-25

A good quarterly update. Enough money in the bank for at lest 12 months. Lots of work on the tablets done and continuing, talking to companies in the US and Germany about continuing the canine trials, I'm guessing the German company may be Merck who recently employed someone from Novartis to head up the animal R&D section. Novartis owned and introduced Monepantel to the market as a sheep treatment so he will be intimately familiar with Monepantel, that cant be a bad thing.

Someone [Sorry cant recall who] said they expect things to happen quickly on the Covid front if the Organoid tests are successful and I agree 100%. The same with the Canine side of things.

It still looks like a nice plump little company with an increasingly interesting drug that works on multiple fronts that is primed for a T/O by a big Pharma shark. Weather its next month or in 12 - 18 months I have no idea.

I hope the PowerPoint presentation for the AGM is an eye catcher and they get the word out.

Market is a sea of red today hopefully we can get out of it without to much of a drop.


All the Best
Pete